2025 年 1 月 22 日，芬兰埃斯波 -
体外诊断行业关键原料全球领先供应商Medix Biochemica宣布收购CANDOR Bioscience GmbH。CANDOR Bioscience位于德国，是优质免疫检测解决方案的开发商和制造商。此次收购既强化了Medix Biochemica高品质体外诊断关键原料产品线，又在试剂开发方面提升了其为IVD试剂生产商提供支持的能力。交易完成后，CANDOR Bioscience高质量的运营将继续保留在德国阿尔高地区旺根。
22 January 2025, Espoo, Finland –
Medix Biochemica, a global leader in the supply of critical raw materials for the in vitro diagnostics (IVD) industry, announced the acquisition of CANDOR Bioscience GmbH, a Germany-based developer and manufacturer of premium immunoassay solutions. The acquisition both strengthens Medix Biochemica’s range of high-quality raw materials to the worldwide IVD industry and enhances its capabilities to support test manufacturers in immunoassay development. Following the transaction, CANDOR Bioscience’s high-quality operations will remain in Wangen im Allgäu, Germany.
CANDOR Bioscience由Tobias Polifke博士和Peter Rauch博士创立于2004年，是一家德国企业，提供种类齐全的优质免疫分析解决方案；产品包括人抗鼠抗体 (HAMA)、干扰阻断剂、表面阻断剂、稳定剂和缓冲液。借助CANDOR Bioscience的解决方案，免疫检测试剂生产商可以提高检测结果的可靠性，简化实验设计、缩短开发流程。
CANDOR Bioscience, founded in 2004 by Dr Tobias Polifke and Dr Peter Rauch, is a German provider of a comprehensive selection of premium solutions for immunoassays, including HAMA and interference blockers, surface blockers, stabilizers and buffer solutions. By using CANDOR Bioscience’s solutions, immunoassay manufacturers can improve reliability of test results, simplify assay designs and reduce process times.
“我们很高兴CANDOR加入Medix Biochemica大家庭！通过与CANDOR的合作、增加免疫检测开发方面的互补专长、凭借一流的优质阻断剂和稳定剂产品线拓宽我们关键体外诊断 (IVD) 原料的供应范围，将进一步强化Medix Biochemica服务客户的能力。我们将携手继续提供超优质的原料、推动诊断技术创新，并且我们期待与CANDOR团队展开成功合作。” Medix Biochemica首席执行官Steve Ferguson表示。
“We are delighted to welcome CANDOR into the Medix Biochemica family. The partnership with CANDOR strengthens Medix Biochemica’s ability to support our customer base by adding complementary expertise in immunoassay development and broadening our offering of critical IVD raw materials with a leading portfolio of premium blockers and stabilizers. Together, we will continue to provide the highest quality raw materials that enable diagnostic innovation, and we look forward to a successful collaboration with the CANDOR team,” says Steve Ferguson, CEO of Medix Biochemica.
CANDOR Bioscience的联合创始人兼董事总经理Tobias Polifke博士和Peter Rauch博士对此次合作倍感兴奋：“与Medix Biochemica携手，对CANDOR而言是一个激动人心的里程碑。我们为自己在免疫检测开发提供差异化、高性能解决方案方面的传统而感到自豪，并且我们与Medix Biochemica一样，致力于质量与创新。通过整合我们的能力与产品，我们将更有能力满足客户不断变化的需求。Medix Biochemica的产品，包括抗体和质控原料，与我们的解决方案完美互补，提升了我们为体外诊断 (IVD) 行业合作伙伴创造的价值。”
Dr Tobias Polifke and Dr Peter Rauch, co-founders and Managing Directors of CANDOR Bioscience, are excited about the partnership: “Joining forces with Medix Biochemica is an exciting milestone for CANDOR. We are proud of our legacy in providing differentiated, high-performance solutions for immunoassay development, and we share Medix Biochemica’s commitment to quality and innovation. By combining our capabilities and offerings, we will be better positioned to support the evolving needs of our customers. Medix Biochemica’s products, including antibodies and quality control materials, perfectly complement our solutions, enhancing the value we offer to partners in the IVD industry”.
